Sign up
Pharma Capital

Fiji Kava bringing products 'from farm to shelf' backed by research and clinical trials

Fiji Kava Ltd (ASX:FIJ) chief executive Zane Yoshida introduces Proactive Investors to the newly-listed company, and explains the history behind as well as market opportunities for kava.

The company aims to bring a range of products "from farm to shelf," supported by strong research and development, and clinical trials with the National Institute of Complementary Medicine.

Taki Mai-branded products are already available for sale online, and Fiji Kava-branded products will be launched in the coming months, available through e-commerce giant Amazon.


View full FIJ profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.